Clinical studies to examine the association of mRNA expression of GREM1, BAG2, OLFM4, TRIP6 and MAGE-A9 and OS in patients with intestinal or diffuse subtype of gastric cancer using different chemotherapeutic agents need to be done. This evidence concerns the gene MAGEA9 and gastric cancer.